TGFB1 and neoplasm: To intervene with excessive TGF-β signalling activity to enhance anti-tumour immunity, varieties of TGF-β antagonists have been developed (Akhurst & Hata, 2012; Flavell et al, 2010; Hawinkels & ten Dijke, 2011).